Compare prices and buy Vesugen from 4 research peptide vendors - also called suppliers or sources. Updated daily.
A synthetic tripeptide (Lys-Glu-Asp / KED, CAS 204271-66-9) in the Khavinson short-peptide family, associated with vascular endothelial tissue. Reported in Russian cell studies to modulate endothelial-cell proliferation and endothelial signaling markers such as endothelin-1. Part of the Cytogen class of ultra-short peptide bioregulators. It has no FDA approval.
For research purposes only. Not medical advice.
Vesugen is a synthetic tripeptide, Lys-Glu-Asp (written KED), from Vladimir Khavinson's short-peptide program. The rest of the family is in Longevity and Bioregulators, where Vesugen and Cardiogen are the vascular and cardiac entries. PubChem's record for Lys-Glu-Asp gives the formula C15H26N4O8 and a molecular weight of about 390.
Two reviews by Khavinson and colleagues assign it to blood vessels. A 2021 table in Molecules lists KED, Vesugen, for regulation of cardiovascular system function, alongside neuroprotection, geroprotection, DNA binding and effects on stem cells and skin fibroblasts. A 2022 table in the International Journal of Molecular Sciences lists it as a vasoprotector, neuroprotector and geroprotector, and its text gives KED as an example of a peptide with several biological activities. For the vascular entry, that table cites the group's 2014 study of endothelial-cell proliferation.
The laboratory work is cell, tissue and animal research, and every study below comes from Khavinson's institute or groups publishing with its staff.
The family's proposed mechanism is direct binding to DNA, and for Vesugen the Ki-67 work above modeled that binding by docking. Computer docking in the 2022 review also scores it within the range its authors read as likely binding to LAT1, an amino-acid transporter.
The human reports PeptideScouter found are small Russian studies, and ClinicalTrials.gov lists no study under its name or its sequence.
A 2014 Russian-language report from a group including Khavinson describes 41 patients with erectile dysfunction attributed to atherosclerosis who received Vesugen alone, and compares blood flow in the main penile arteries before and after treatment. It reports a significant improvement, and its abstract describes no control group (Kitachev, Advances in Gerontology, 2014).
Vesugen also appears in several of the small Russian studies that the Pinealon page covers. The 2015 study among them gave either peptide to adults with organic brain syndrome, and its abstract reports a pro-oxidant effect and a fall in CD34-positive blood stem cells, which the authors read as inhibited blood-cell formation (Meshchaninov, Advances in Gerontology, 2015).
PeptideScouter found no US regulatory record for Vesugen. As of October 21, 2026, it appears in none of these:
In Russia, the state-registration register of Rospotrebnadzor, the consumer-protection agency, lists Vesugen tablets, capsules and a sublingual liquid as dietary supplements described as a source of peptides, under two 2025 certificates. The entries give no sequence, and the registrations fall under the customs union's technical regulations for food, not the medicines register.
Only in small Russian studies, and ClinicalTrials.gov lists none of them as of October 2026. A 2014 Russian-language report describes 41 patients with erectile dysfunction attributed to atherosclerosis who received the tripeptide Lys-Glu-Asp alone, and reports better blood flow in the main penile arteries after treatment than before. Its abstract describes no control group. A 2015 Russian study gave Vesugen or the related peptide Pinealon to adults with organic brain syndrome and reported a pro-oxidant effect and a fall in circulating CD34-positive blood stem cells.
From its developers' cell studies. Vladimir Khavinson's group lists the tripeptide Lys-Glu-Asp under cardiovascular regulation in its 2021 review and as a vasoprotector in its 2022 review, which cites a 2014 study in which it raised the proliferation marker Ki-67 in cultured vascular endothelial cells. A 2016 study from the same institute reported that it normalized endothelin-1 expression, which rose in in-vitro models of atherosclerosis and restenosis, and raised sirtuin-1 expression. Apart from small Russian clinical reports, the published work consists of cell, tissue and animal experiments.
PeptideScouter found no US regulatory record for it. As of October 21, 2026, Vesugen does not appear in Drugs@FDA, in either table of FDA's Category 2 list of bulk drug substances raising significant safety risks, in FDA's lists of substances nominated for compounding under Sections 503A and 503B, or among the substances FDA named for its July 2026 and next Pharmacy Compounding Advisory Committee meetings. FDA's substance registry has no record of it and no FDA warning letter names it. In Russia, the Rospotrebnadzor register lists Vesugen tablets, capsules and a sublingual liquid as dietary supplements, a food registration and not a medicine approval.
Yes. Both names refer to the tripeptide Lys-Glu-Asp, also written KED. Vezugen is a transliteration of the Russian name, used in a 2014 clinical report, and some of the developers' cell studies refer to the tripeptide by the laboratory code T-38.
Vesugen is sold by 4 research peptide vendors indexed on PeptideScouter, with 4 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
All 4 indexed research peptide vendors currently have Vesugen in stock. Stock state is refreshed daily from each vendor's catalog.
Disguised Alpha currently lists Vesugen at $2.50/mg, the lowest listed price across 4 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $2.25/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 4 vendors listing Vesugen publish a PeptideScouter code, worth 10% to 20% off. Applied, the lowest effective price falls from $2.50/mg listed to $2.25/mg at Disguised Alpha. Each vendor's code is shown beside its price in the table above.
Vesugen ranges from $2.50/mg to $4.50/mg across 4 listings from 4 research peptide vendors, normalized to USD per milligram and refreshed daily.
4 research peptide vendors currently list Vesugen on PeptideScouter. We track 4 listings across size and kit variants.
Vesugen's CAS Registry Number is 204271-66-9.
